This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 3 Study to Compare the Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified April 2017 by AB Science
Information provided by (Responsible Party):
AB Science Identifier:
First received: April 13, 2017
Last updated: April 20, 2017
Last verified: April 2017
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus corresponding placebo in combination with riluzole in the treatment of patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).

Condition Intervention Phase
ALS Drug: Masitinib Mesylate Drug: Riluzole 50Mg Tablet Drug: Placebo Oral Tablet Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Resource links provided by NLM:

Further study details as provided by AB Science:

Primary Outcome Measures:
  • Absolute change from baseline to week 48 in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised. [ Time Frame: Week 48 ]
    Revised-ALS Functional Rating Score

Secondary Outcome Measures:
  • Change in ALSAQ-40 from baseline to week 48 [ Time Frame: Week 48 ]
    ALS quality of life patient questionnaire

Estimated Enrollment: 406
Anticipated Study Start Date: September 1, 2017
Estimated Study Completion Date: September 1, 2019
Estimated Primary Completion Date: September 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Masitinib
masitinib in combination with riluzole
Drug: Masitinib Mesylate
treatment per os
Drug: Riluzole 50Mg Tablet
treatment per os
Placebo Comparator: placebo
placebo in combination with riluzole
Drug: Riluzole 50Mg Tablet
treatment per os
Drug: Placebo Oral Tablet
treatment per os


Ages Eligible for Study:   18 Years to 81 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient diagnosed with laboratory supported, clinically probable or definite ALS
  • Patient treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior to screening
  • Patient with adequate organ function at screening

Exclusion Criteria:

  • Patient who underwent tracheostomy and /or gastrostomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03127267

Contact: Angela Genge (514) 398-3868
Contact: Alain Moussy

Sponsors and Collaborators
AB Science
  More Information

Responsible Party: AB Science Identifier: NCT03127267     History of Changes
Other Study ID Numbers: AB14008
Study First Received: April 13, 2017
Last Updated: April 20, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Motor Neuron Disease
Neurodegenerative Diseases
TDP-43 Proteinopathies
Neuromuscular Diseases
Proteostasis Deficiencies
Metabolic Diseases
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents processed this record on September 25, 2017